Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SCOTT LAWRENCE FLEISCHAUER

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1285789065
CMS profile
57953
Location
ARLINGTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$290.60

12 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $274.20 11
Education $16.40 1

By paying entity

PY2025 · entire year · sorted by reported total

Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SCOTT LAWRENCE FLEISCHAUER

NPI 1285789065 · CMS profile ID 57953

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

ARLINGTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1285789065?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SCOTT LAWRENCE FLEISCHAUER, NPI 1285789065, CMS profile ID 57953. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1285789065?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). SCOTT LAWRENCE FLEISCHAUER, NPI 1285789065, CMS profile ID 57953. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1285789065?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
SCOTT LAWRENCE FLEISCHAUER, NPI 1285789065, CMS profile ID 57953, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1285789065?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

12 matching records · $290.60 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 12 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–12 of 12.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
BeOne Medicines USA, Inc. $13.6712/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202910001 CMS
GlaxoSmithKline, LLC. $24.4210/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190686163 CMS
ARRAY BIOPHARMA INC $20.3906/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228817199 CMS
PFIZER INC. $27.5406/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228930680 CMS
Exelixis Inc. $26.5305/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1218803999 CMS
Novartis Pharmaceuticals Corporation $15.6105/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200355036 CMS
E.R. Squibb & Sons, L.L.C. $19.4605/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184451156 CMS
Incyte Corporation $27.0205/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226100501 CMS
ARRAY BIOPHARMA INC $26.6104/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228857315 CMS
Aveo Pharmaceuticals, Inc. $26.8103/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1199898852 CMS
INTUITIVE SURGICAL, INC. $46.1403/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236649042 CMS
Takeda Pharmaceuticals U.S.A., Inc. $16.4002/03/2025 Education No dispute reported Delay: No
Change: NEW
06/30/2026 1224102466 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $76.24 8
PY2020 $18.82 2
PY2021 $2,731.92 3
PY2022 $1,144.93 5
PY2023 $23.72 1
PY2024 $84.25 4
PY2025 $290.60 12

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2023 Principal investigator $82,946.55 11
PY2022 Principal investigator $30,457.88 33
PY2021 Principal investigator $116,928.89 44
PY2020 Recipient $656.00 1
PY2020 Principal investigator $144,873.80 55
PY2019 Recipient $3,698.00 1
PY2019 Principal investigator $153,312.17 57

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

44 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 BeiGene, Ltd. $56,400.00 12/21/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY-ARLINGTON SOUTH
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment with Ibrutinib No dispute reported 06/30/2026 843879543
Principal investigator 1 Seagen Inc. $175.00 12/15/2021 Non-covered Recipient Entity
ARLINGTON CANCER CENTER
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above No dispute reported 06/30/2026 792669569
Principal investigator 1 Seagen Inc. $151.00 12/15/2021 Non-covered Recipient Entity
ARLINGTON CANCER CENTER
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above No dispute reported 06/30/2026 792669573
Principal investigator 1 PFIZER INC. $1,250.00 12/08/2021 Non-covered Recipient Entity
US Oncology Research LLC
A PHASE 2 NON RANDOMIZED OPEN LABEL SINGLE ARM MULTI CENTER STUDY OF TALAZOPARIB FOR NEOADJUVANT TREATMENT OF GERMLINE BRCA12 MUTATION PATIENTS WITH EARLY HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER No dispute reported 06/30/2026 832563845
Principal investigator 1 Incyte Corporation $850.00 10/15/2021 Non-covered Recipient Entity
TX ONC
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831055235
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $638.00 10/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786497605
Principal investigator 1 Seagen Inc. $175.00 10/15/2021 Non-covered Recipient Entity
ARLINGTON CANCER CENTER
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above No dispute reported 06/30/2026 792669549
Principal investigator 1 Seagen Inc. $480.00 10/15/2021 Non-covered Recipient Entity
ARLINGTON CANCER CENTER
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above No dispute reported 06/30/2026 792669555
Principal investigator 1 Seagen Inc. $180.00 10/15/2021 Non-covered Recipient Entity
ARLINGTON CANCER CENTER
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above No dispute reported 06/30/2026 792669557
Principal investigator 1 Seagen Inc. $260.00 10/15/2021 Non-covered Recipient Entity
ARLINGTON CANCER CENTER
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above No dispute reported 06/30/2026 792669559
Principal investigator 1 Seagen Inc. $25.00 10/15/2021 Non-covered Recipient Entity
ARLINGTON CANCER CENTER
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above No dispute reported 06/30/2026 792669561
Principal investigator 1 Seagen Inc. $180.00 10/15/2021 Non-covered Recipient Entity
ARLINGTON CANCER CENTER
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above No dispute reported 06/30/2026 792669587
Principal investigator 1 Seagen Inc. $180.00 10/15/2021 Non-covered Recipient Entity
ARLINGTON CANCER CENTER
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above No dispute reported 06/30/2026 792669589
Principal investigator 1 Seagen Inc. $25.00 10/15/2021 Non-covered Recipient Entity
ARLINGTON CANCER CENTER
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above No dispute reported 06/30/2026 792669591
Principal investigator 1 Incyte Corporation $1,000.00 10/07/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831122925
Principal investigator 1 Incyte Corporation $573.89 09/29/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831121585
Principal investigator 1 Seagen Inc. $151.00 09/15/2021 Non-covered Recipient Entity
ARLINGTON CANCER CENTER
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above No dispute reported 06/30/2026 792669583
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,125.00 07/26/2021 Non-covered Recipient Entity
Us Oncology Research Llc
An Open-label Single-arm Phase II Study of Regorafenib and Nivolumab in Patients with Mismatch Repair-Proficient (pMMR)/Microsatellite Stable (MSS) Colorectal Cancer (CRC) No dispute reported 06/30/2026 821953609
Principal investigator 1 Incyte Corporation $850.00 07/15/2021 Non-covered Recipient Entity
TX ONC
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831055213
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $638.00 07/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786497603
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,500.00 06/18/2021 Non-covered Recipient Entity
Us Oncology Res Llc
A Phase IIIb/IV Safety Trial of Nivolumab (BMS-936558) in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen No dispute reported 06/30/2026 819906215
Principal investigator 1 Incyte Corporation $489.00 06/15/2021 Non-covered Recipient Entity
TX ONC
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831055103
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 05/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786497599
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 05/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786497601
Principal investigator 1 Eli Lilly and Company $1,749.00 05/04/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 819467609
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,125.00 04/23/2021 Non-covered Recipient Entity
Us Oncology Research Llc
An Open-label Single-arm Phase II Study of Regorafenib and Nivolumab in Patients with Mismatch Repair-Proficient (pMMR)/Microsatellite Stable (MSS) Colorectal Cancer (CRC) No dispute reported 06/30/2026 821953653
Principal investigator 1 Incyte Corporation $850.00 04/15/2021 Non-covered Recipient Entity
TX ONC
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831055097
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $638.00 04/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786497597
Principal investigator 1 Seagen Inc. $1,020.00 04/15/2021 Non-covered Recipient Entity
ARLINGTON CANCER CENTER
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above No dispute reported 06/30/2026 792669497
Principal investigator 1 Seagen Inc. $151.00 04/15/2021 Non-covered Recipient Entity
ARLINGTON CANCER CENTER
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above No dispute reported 06/30/2026 792669501
Principal investigator 1 Seagen Inc. $300.00 04/15/2021 Non-covered Recipient Entity
ARLINGTON CANCER CENTER
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above No dispute reported 06/30/2026 792669503
Principal investigator 1 Seagen Inc. $1,020.00 04/15/2021 Non-covered Recipient Entity
ARLINGTON CANCER CENTER
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above No dispute reported 06/30/2026 792669527
Principal investigator 1 Seagen Inc. $1,020.00 04/15/2021 Non-covered Recipient Entity
ARLINGTON CANCER CENTER
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above No dispute reported 06/30/2026 792669529
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $4,500.00 04/02/2021 Non-covered Recipient Entity
Us Oncology Research Llc
An Open-label Single-arm Phase II Study of Regorafenib and Nivolumab in Patients with Mismatch Repair-Proficient (pMMR)/Microsatellite Stable (MSS) Colorectal Cancer (CRC) No dispute reported 06/30/2026 821953465
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 03/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786497595
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $190.00 02/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786497593
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $21,091.00 02/04/2021 Non-covered Recipient Entity
Us Oncology Res Llc
Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices No dispute reported 06/30/2026 819905037
Principal investigator 1 Celgene Corporation $2,142.00 01/15/2021 Non-covered Recipient Entity
Texas Oncology
Connect MM- The Multiple Myeloma Disease Registry No dispute reported 06/30/2026 807115557
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,824.00 01/15/2021 Non-covered Recipient Entity
Texas Oncology
Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in US Community Oncology Practices No dispute reported 06/30/2026 819901763
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,275.00 01/15/2021 Non-covered Recipient Entity
Texas Oncology
Phase IIIb IV Safety Trial of Nivolumab BMS-936558 in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 819901831
Principal investigator 1 Eli Lilly and Company $2,930.00 01/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 819468473
Principal investigator 1 Incyte Corporation $850.00 01/15/2021 Non-covered Recipient Entity
TX ONC
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 831055079
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $638.00 01/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) No dispute reported 06/30/2026 786497591
Principal investigator 1 PFIZER INC. $3,750.00 01/12/2021 Non-covered Recipient Entity
US Oncology Research LLC
A PHASE 2 NON RANDOMIZED OPEN LABEL SINGLE ARM MULTI CENTER STUDY OF TALAZOPARIB FOR NEOADJUVANT TREATMENT OF GERMLINE BRCA12 MUTATION PATIENTS WITH EARLY HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER No dispute reported 06/30/2026 832670785